BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Press Releases

I Peace, Inc. Introduces Clinical-Grade iPS Cell Custom Manufacturing Service

By Leave a Comment

PALO ALTO, Calif., May 15, 2020 — I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up focusing on Nobel Prize-wining technology “induced pluripotent stem cell (iPSC)” began manufacturing clinical-grade iPSCs. We are now officially taking orders for custom manufacturing of clinical-grade iPSCs from institutions around the world.

On March 11, 2020, the company received a license to manufacture clinical-grade cells from Japan’s Ministry of Health, Labour and Welfare for its cell manufacturing facility located in Kyoto, Japan. [Read more…]

FDA Approves Two Emergency INDs to Administer Organicell Flow for COVID-19

By Leave a Comment

First Patients treated with Organicell Flow through “Emergency Single Patient Compassionate Use” designation

MIAMI, May 19, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that on May 11, 2020, the U.S. Food and Drug Administration (FDA) authorized two Emergency Compassionate Use Investigational New Drug applications (eINDs), each for a single patient severely ill from COVID-19. These critical patients have received immediate administration of Organicell Flow. [Read more…]

Mesoblast to Enroll 300 Patients in COVID-19 Trial of Stem Cell Therapy Remestemcel-L

By 1 Comment

Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment

NEW YORK, April 30, 2020 — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic mesenchymal stem cell therapy remestemcel-L provides a survival benefit in moderate/severe acute respiratory distress syndrome (ARDS) due to COVID-19 has commenced enrollment. [Read more…]

Aspire Health Science Announces Strategic Partnership with NeoProgen for Development and Manufacturing of NeoProgen’s cell-based therapy

By Leave a Comment

ORLANDO, Florida, May 6th, 2020– Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered GMP manufacturing facility specialized in the research, development, and manufacturing of cell-based therapies, is pleased to announce a collaboration with NeoProgen, Inc.

NeoProgen, a Baltimore-based company led by Medtech entrepreneur Bill Niland, is a preclinical stage therapeutics company specializing in the development of novel cellbased cardiac therapies for heart regeneration. Similar to Mr. Niland’s earlier venture with Harpoon Medical, NeoProgen has origins in research at the University of Maryland, Baltimore. That is where Dr. Sunjay Kaushal, a leading pediatric cardiac surgeon, discovered that a specific kind of neonatal cardiac progenitor/ stem cells (nCPCs), obtained from discarded cardiac tissue biopsies, are extremely effective in regenerating muscle tissue in the heart. [Read more…]

Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19

By 2 Comments

MIAMI, May 05, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Organicell Flow, for patients diagnosed with moderate to severe acute respiratory syndrome (SARS) due to COVID-19 infection. [Read more…]

BioInformant's World-Class Clients